$695 | Single User
$2850 | Site License
$5650 | Global License

Pharma and the mHealth Revolution - engaging with mobile-enabled physicians and HCPs
[Published by FirstWord Pharma]

Published by FirstWord Pharma: 01 Feb 2013 | 37 | In Stock
Related Topics: AstraZeneca , Boehringer Ingelheim , Compliance , GlaxoSmithKline , Lilly

Introduction

Introduction


It’s time to click on this.


The media’s dubbed them ‘a doctor in your pocket’ and ‘health care helpers’. Yet despite the explosion of mobile apps in other industries, pharma has generally been slow to exploit the possibilities they represent. What are the hurdles facing the industry and who are the leaders overcoming them? How can companies develop a mHealth approach that both addresses end-user needs and key messaging? What does pharma need to know about regulatory and legal hurdles?


Concisely written and expertly researched, this FirstWord Dossier report succinctly addresses the issues surrounding the emerging mHealth industry—and finds the answers.


Scope


Report Overview


Offering a compelling case for pharma to firmly establish its voice in mHealth, the report contains detailed insight into the opportunities app development represents. Encompassing the full range of questions demanded by the industry, the report includes expert insight from both those in pharma currently working ahead of the curve and mHealth developers themselves.


Whether your company is looking to expand into mHealth apps or seeking sound advice on a way forward, Pharma and the mHealth Revolution - engaging with mobile-enabled physicians and HCPs has the answers.


Highlights


Key Report Features


  • Convincing arguments for further involvement from pharma in developing mHealth apps for healthcare providers

  • Detailed insight into five major pharma mHealth projects

  • Methodologies for determining the platforms on which mHealth apps should be launched

  • Advice on how to maximise end-user needs to make mHealth products popular with health care professionals

  • Insight into navigating legal, regulatory and intellectual property issues

  • Solid predictions of future mHealth growth

  • Case study of how one major pharma company has evolved its mHealth strategy

  • Puchase Reasons


    Key Benefits


  • Discover how to develop an mHealth approach that aligns with company goals

  • Learn the key lessons of optimising apps and websites for healthcare providers

  • Learn how to navigate the main road bumps, including legal, regulatory and intellectual property issues

  • Gain insight into what the leaders in the field know and how they’re making mHealth apps work for them

  • Get access to detailed case studies from companies such as Eli Lilly, AstraZeneca, Johnson & Johnson, AliveCor and GSK

  • Key Questions Answered


  • When should a pharma company enter the mHealth market?

  • What approach should be taken in answering both company strategy and end-user needs?

  • What are the main hurdles facing the industry and how can they be overcome?

  • What realities do app designers for international markets face?

  • How can apps be developed for maximum usage across HCPs?

  • What are the guidelines for designing apps for tablet or smartphones?

  • Who Should Read This Report


  • Pharma medical affairs directors

  • Marketing executives

  • Compliance directors and legal teams

  • IT managers

  • PR firms with interests in the pharmaceutical industry

  • Digital marketing agencies

  • App and web designers

  • Expert Views Include:



    Dr. Dave Albert, Co-founder and Chief Medical Officer, AliveCor


    Orion Armon, Partner, Cooley LLP


    Kenneth Bennett, Senior Director, IS Business Partner, Sanofi US division


    Lena Feygin, Managing Director, WeMultiply


    Shwen Gwee, Vice President, Digital Health, Edelman


    Peter Justason, Director, eMarketing, Purdue Pharma


    Duncan Learmouth, Senior Vice President, Developing Countries & Market Access, GlaxoSmithKline


    Jonathan Martin, Director of Education and Awareness Programs, National Marfan Foundation


    Dr. Patricia Mechael, Executive Director, mHealth Alliance


    Brian Meltzer, Executive Director, R&D Innovation, Purdue Pharma


    Dr. Satish Misra, Managing Editor, iMedicalApps and member, Steering Committee, Johns Hopkins Global mHealth Initiative


    Scott Morrison, Vice President, Information Systems, Boehringer Ingelheim


    Judy Wade, ex-CEO, AliveCor


    Key Quotes


    “The business case for pharma to engage in mHealth makes a lot of sense. But pharma has been quite slow to really embrace things in mobile health in a strategic or systematic way.” Dr. Patricia Mechael, executive director, mHealth Alliance


    “There is substantial opportunity for pharmaceutical companies to be involved; it’s just that they have to walk that fine line between providing a service to the patient population and having what they’re doing viewed as just a kind of marketing. As soon as it gets perceived as the latter, all the alarm bells will go off.” Dr. Satish Misra, managing editor, iMedicalApps

    Table of Contents
    for Pharma and the mHealth Revolution - engaging with mobile-enabled physicians and HCPs [Published by FirstWord Pharma]

    • 1.Executive summary

      2.Introduction

      3.Possibilities

      3.1. On the go

      3.2. Device ownership

      3.3. Medical practice has changed

      3.4. Using mHealth devices

      3.5. Topic diversity

      3.6. Global diversity

      4.Realities

      4.1.The pioneers

      4.2. Rules of engagement

      4.3. Phone or web?

      5.Pharma’s role in mHealth - Five detailed examples

      5.1. Eli Lilly: Glucagon mobile app

      5.2. AstraZeneca: EGFR mutation test

      5.3. Johnson & Johnson: BlackBag

      5.4. AliveCor: Heart monitor

      5.5. GlaxoSmithKline: Mozambique vaccines programme

      6.Case Study

      6.1. Sanofi’s mHealth strategy

      6.2. A variety of offerings

      6.3. The bottom line

      7.Uncertainties

      7.1. Regulators weighing options

      7.2. A Congressional approach

      7.3. Intellectual property concerns

      7.4. User hesitancy

      8.What’s ahead?

      8.1. Predicted growth

      8.2. Emerging technology

      8.3. Listening to the users

      8.4. Assuring efficacy

      8.5. The final requirement: Patience

      9. Acknowledgements

    Additional Details

    Publisher

    FirstWord Pharma

    Publisher Information

    Reference

    37 |

    Number of Pages

    83

    Report Format

    PDF

    FirstWord Pharma Reports

    Related Reports

    TitleDate PublishedPrice fromMore Details
    The Top 10 Pharma Companies in 2017
    Introduction...leading drivers and resistors to growthWith many of the world's largest pharmaceutica...
    01 Mar 2013 by FirstWord Pharma USD $395 More Info
    Big Data in Pharma Marketing
    IntroductionBig data - the huge volume of digital data generated worldwide - continues to grow expon...
    01 Jan 2013 by FirstWord Pharma USD $695 More Info
    Social and Mobile Pharma - the State of the Digital Landscape
    IntroductionTightly-regulated and conservative in outlook, the pharmaceutical industry has largely b...
    01 Nov 2012 by FirstWord Pharma USD $695 More Info
    Pharma and Payers – Building Better Relationships
    IntroductionChanges in the healthcare landscape have put payers (public and private) under mounting ...
    01 Sep 2012 by FirstWord Pharma USD $695 More Info
    Pharma Reputations: Managing Perceptions
    IntroductionPharma is no stranger to the idea of nurturing and defending corporate reputations. But...
    01 Aug 2012 by FirstWord Pharma USD $645 More Info
    Pharma's Future Role in CME
    IntroductionOver the last 10 years, every aspect of continuing medical education (CME) has endured m...
    01 Aug 2012 by FirstWord Pharma USD $695 More Info
    Pharma sales force shape, size and structure — where next?
    IntroductionRetarget your sales force with new resourcesSales force management now plays a critical ...
    01 Jul 2012 by FirstWord Pharma USD $695 More Info
    Inside China’s Healthcare Reforms: Opportunities for Multinational Pharma
    IntroductionIn 2009, China’s government announced plans to invest RMB1.13 trillion (0 billion) in...
    01 Jun 2012 by FirstWord Pharma USD $995 More Info
    Meeting KOL Needs: What Pharma Needs to Know
    IntroductionThe role of the Key Opinion Leader (KOL) has changed over the past 30 years. And it's ab...
    01 Feb 2012 by FirstWord Pharma USD $1,445 More Info
    Academic Detailing: Pharma Fights Back
    IntroductionEver since it was introduced three decades ago, academic detailing—which now increasingl...
    01 Jan 2012 by FirstWord Pharma USD $745 More Info

    This report is published by FirstWord Pharma

    Download Free Report Summary PDF

    Pharma and the mHealth Revolution - engaging with mobile-enabled physicians and HCPs [Published by FirstWord Pharma] | Download PDF Summary

    Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

    Ordering Information

    Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

    Accepted Card Types

    Payment

    Buy now using our secure payment system.

    We Stock...